Literature DB >> 24218456

Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming.

Michal Marzec1, Krzysztof Halasa, Xiaobin Liu, Hong Y Wang, Mangeng Cheng, Donald Baldwin, John W Tobias, Stephen J Schuster, Anders Woetmann, Qian Zhang, Suzanne D Turner, Niels Ødum, Mariusz A Wasik.   

Abstract

Anaplastic lymphoma kinase (ALK), physiologically expressed only by nervous system cells, displays a remarkable capacity to transform CD4(+) T lymphocytes and other types of nonneural cells. In this study, we report that activity of nucleophosmin (NPM)/ALK chimeric protein, the dominant form of ALK expressed in T cell lymphomas (TCLs), closely resembles cell activation induced by IL-2, the key cytokine supporting growth and survival of normal CD4(+) T lymphocytes. Direct comparison of gene expression by ALK(+) TCL cells treated with an ALK inhibitor and IL-2-dependent ALK(-) TCL cells stimulated with the cytokine revealed a very similar, albeit inverse, gene-regulation pattern. Depending on the analysis method, up to 67% of the affected genes were modulated in common by NPM/ALK and IL-2. Based on the gene expression patterns, Jak/STAT- and IL-2-signaling pathways topped the list of pathways identified as affected by both IL-2 and NPM/ALK. The expression dependence on NPM/ALK and IL-2 of the five selected genes-CD25 (IL-2Rα), Egr-1, Fosl-1, SOCS3, and Irf-4-was confirmed at the protein level. In both ALK(+) TCL and IL-2-stimulated ALK(-) TCL cells, CD25, SOCS3, and Irf-4 genes were activated predominantly by the STAT5 and STAT3 transcription factors, whereas transcription of Egr-1 and Fosl-1 was induced by the MEK-ERK pathway. Finally, we found that Egr-1, a protein not associated previously with either IL-2 or ALK, contributes to the cell proliferation. These findings indicate that NPM/ALK transforms the target CD4(+) T lymphocytes, at least in part, by using the pre-existing, IL-2-dependent signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24218456      PMCID: PMC3889215          DOI: 10.4049/jimmunol.1300744

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

1.  Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's.

Authors:  M Hatakeyama; M Tsudo; S Minamoto; T Kono; T Doi; T Miyata; M Miyasaka; T Taniguchi
Journal:  Science       Date:  1989-05-05       Impact factor: 47.728

Review 2.  T-cell growth factor.

Authors:  K A Smith
Journal:  Immunol Rev       Date:  1980       Impact factor: 12.988

3.  NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.

Authors:  Roberto Chiarle; Jerald Z Gong; Ilaria Guasparri; Anna Pesci; Jonjing Cai; Jian Liu; William J Simmons; Girish Dhall; Jennifer Howes; Roberto Piva; Giorgio Inghirami
Journal:  Blood       Date:  2002-11-07       Impact factor: 22.113

Review 4.  The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma.

Authors:  Ronnie M Abraham; Qian Zhang; Niels Odum; Mariusz A Wasik
Journal:  Cancer Biol Ther       Date:  2011-12-15       Impact factor: 4.742

5.  Evidence for a role for the phosphotyrosine-binding domain of Shc in interleukin 2 signaling.

Authors:  K S Ravichandran; V Igras; S E Shoelson; S W Fesik; S J Burakoff
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

6.  Interleukin-2 induces tyrosine phosphorylation of the vav proto-oncogene product in human T cells: lack of requirement for the tyrosine kinase lck.

Authors:  G A Evans; O M Howard; R Erwin; W L Farrar
Journal:  Biochem J       Date:  1993-09-01       Impact factor: 3.857

Review 7.  Interleukin-2: inception, impact, and implications.

Authors:  K A Smith
Journal:  Science       Date:  1988-05-27       Impact factor: 47.728

8.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

9.  Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5).

Authors:  J Fujimoto; M Shiota; T Iwahara; N Seki; H Satoh; S Mori; T Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

Review 10.  Interleukin-2.

Authors:  K A Smith
Journal:  Curr Opin Immunol       Date:  1992-06       Impact factor: 7.486

View more
  12 in total

1.  A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening.

Authors:  Jing-Ping Zhang; Zhihui Song; Hong-Bo Wang; Lang Lang; Yuan-Zhong Yang; Wenming Xiao; Daniel E Webster; Wei Wei; Stefan K Barta; Marshall E Kadin; Louis M Staudt; Masao Nakagawa; Yibin Yang
Journal:  Blood       Date:  2019-05-31       Impact factor: 22.113

2.  Induction of Transcriptional Inhibitor HES1 and the Related Repression of Tumor-Suppressor TXNIP Are Important Components of Cell-Transformation Program Imposed by Oncogenic Kinase NPM-ALK.

Authors:  Qian Zhang; Hong Y Wang; Anindita Nayak; Selene Nunez-Cruz; Artur Slupianek; Xiaobin Liu; Johnvesly Basappa; Jing-Song Fan; Seble Chekol; Reza Nejati; Agata M Bogusz; Suzanne D Turner; Kunchithapadam Swaminathan; Mariusz A Wasik
Journal:  Am J Pathol       Date:  2022-05-28       Impact factor: 5.770

3.  High Levels of miR-7-5p Potentiate Crizotinib-Induced Cytokilling and Autophagic Flux by Targeting RAF1 in NPM-ALK Positive Lymphoma Cells.

Authors:  Domenico Sorrentino; Julie Frentzel; Géraldine Mitou; Rafael B Blasco; Avédis Torossian; Coralie Hoareau-Aveilla; Chiara Pighi; Manon Farcé; Fabienne Meggetto; Stéphane Manenti; Estelle Espinos; Roberto Chiarle; Sylvie Giuriato
Journal:  Cancers (Basel)       Date:  2020-10-13       Impact factor: 6.639

4.  Id3 Restricts γδ NKT Cell Expansion by Controlling Egr2 and c-Myc Activity.

Authors:  Baojun Zhang; Anjun Jiao; Meifang Dai; David L Wiest; Yuan Zhuang
Journal:  J Immunol       Date:  2018-07-16       Impact factor: 5.422

5.  STAT3/5-Dependent IL9 Overexpression Contributes to Neoplastic Cell Survival in Mycosis Fungoides.

Authors:  Pablo A Vieyra-Garcia; Tianling Wei; David Gram Naym; Simon Fredholm; Regina Fink-Puches; Lorenzo Cerroni; Niels Odum; John T O'Malley; Robert Gniadecki; Peter Wolf
Journal:  Clin Cancer Res       Date:  2016-02-05       Impact factor: 12.531

Review 6.  From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL).

Authors:  Michael T Werner; Qian Zhang; Mariusz A Wasik
Journal:  Cancers (Basel)       Date:  2017-10-16       Impact factor: 6.639

Review 7.  Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.

Authors:  Lucy Hare; G A Amos Burke; Suzanne D Turner
Journal:  Cancers (Basel)       Date:  2021-11-29       Impact factor: 6.639

8.  Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy.

Authors:  Antoine Buetti-Dinh; Thomas O'Hare; Ran Friedman
Journal:  PLoS One       Date:  2016-09-26       Impact factor: 3.240

9.  Challenging perspectives on the cellular origins of lymphoma.

Authors:  Tim I M Malcolm; Daniel J Hodson; Elizabeth A Macintyre; Suzanne D Turner
Journal:  Open Biol       Date:  2016-09       Impact factor: 6.411

Review 10.  The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL).

Authors:  Ivonne A Montes-Mojarro; Julia Steinhilber; Irina Bonzheim; Leticia Quintanilla-Martinez; Falko Fend
Journal:  Cancers (Basel)       Date:  2018-04-04       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.